

Administration

PATIENT GROUP DIRECTION (PGD) FOR

LIDOCAINE (LIGNOCAINE) 0.5%, 1% & 2% INJECTION

YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

Clinical Condition																									
Indication	For local anaesthesia																								
Inclusion criteria	Patients 18 years and over requiring analgesia due to intra-articular or intralesional injection																								
Exclusion criteria If any of the following apply the PGD CANNOT be used and the patient must be referred to a prescriber	Patients under 18 years of age. Previous allergic reactions to local anaesthetics of the amide type. Pregnancy. Bleeding disorders and warfarin People with porphyria																								
Cautions - Seek further advice from doctor before proceeding and document advice	Dose used must take into account the patient's age, weight, physique, clinical condition, the degree of vascularity of the area involved and the duration of the administration. Great care must be taken to avoid accidental intra-venous injection Maximum arterial plasma concentrations occur within 10-25 minutes therefore patients should be observed for 30 minutes following injection. Any condition where higher doses of lidocaine may be problematic but specifically Hypovolaemia (e.g. through fluid loss); Known impaired cardiac function; bradycardia (Pulse rate less than 60 beats per minute); epilepsy; impaired renal / hepatic function; myasthenia gravis.																								
Action if patient declines or is excluded	Offer alternative conventional measures and / or refer to doctor/orthopaedic practitioner as appropriate																								
Drug Details																									
Name, form & strength of medicine	Lidocaine hydrochloride: <table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th colspan="2">Strength</th> <th>Ampoule size</th> <th>Total dose</th> </tr> </thead> <tbody> <tr> <td>0.5%</td> <td>5mg in 1ml</td> <td>2ml ampoules</td> <td>10mg</td> </tr> <tr> <td>1%</td> <td>10mg in 1ml</td> <td>2ml ampoules</td> <td>20mg</td> </tr> <tr> <td>1%</td> <td>10mg in 1ml</td> <td>5ml ampoules</td> <td>50mg</td> </tr> <tr> <td>2%</td> <td>20mg in 1ml</td> <td>2ml ampoules</td> <td>40mg</td> </tr> <tr> <td>2%</td> <td>20mg in 1ml</td> <td>5ml ampoules</td> <td>100mg</td> </tr> </tbody> </table>	Strength		Ampoule size	Total dose	0.5%	5mg in 1ml	2ml ampoules	10mg	1%	10mg in 1ml	2ml ampoules	20mg	1%	10mg in 1ml	5ml ampoules	50mg	2%	20mg in 1ml	2ml ampoules	40mg	2%	20mg in 1ml	5ml ampoules	100mg
Strength		Ampoule size	Total dose																						
0.5%	5mg in 1ml	2ml ampoules	10mg																						
1%	10mg in 1ml	2ml ampoules	20mg																						
1%	10mg in 1ml	5ml ampoules	50mg																						
2%	20mg in 1ml	2ml ampoules	40mg																						
2%	20mg in 1ml	5ml ampoules	100mg																						
Legal status	Prescription Only Medicine (POM)																								
Route/Method	Intra-articular, Periarticular, Intrabursal, Tendon sheath administration																								

Administration

PATIENT GROUP DIRECTION (PGD) FOR






LIDOCAINE (LIGNOCAINE) 0.5%, 1% & 2% INJECTION

Dosage	As required to maintain local anaesthesia. Usually doses above 20mg are not needed. Lidocaine must not be mixed with a corticosteroid in the syringe prior to injection
Frequency	Single administration
Quantity to administer	Maximum dose 100mg
Side effects	High doses may produce confusion, respiratory depression, convulsions, bradycardia.
Advice to patient/carer	Advise patient normal sensation may take several hours to return fully.
Follow up	The GP should be informed of the treatment in a timely manner.
Staff Characteristics	
Professional qualifications	Registered physiotherapists and podiatrists
Specialist competencies or qualifications	After discussion with and approval of departmental lead:- Successful completion of the A.C.P.O.M, O.M.S, or S.O.M. M. Diploma in Injection Therapy or similar Post Graduate level Injection Therapy course (for physiotherapists), or successful completion of certificated steroid therapy course (for podiatrists). Has undertaken appropriate training for working under PGDs for the supply and administration of medicines Has undertaken training in the management of anaphylaxis
Continuing education & training	It is the responsibility of the individual to keep up-to-date with clinical developments as part of their continued professional development.
Referral Arrangements and Audit Trail	
Records/audit trail	Patient's name, address, date of birth and consent given, Contact details of GP, Diagnosis, Dose and form administered, batch details and expiry date. Site of injection. Advice given to patient (including side effects). Signature/name of staff who administered the treatment. Details of any adverse drug reaction and actions taken including documentation in the patient's medical record. Referral arrangements (including self-care). Complete departmental PGD log sheet.
References/Resources and comments	Current versions of Summary of Product Characteristics, BNF, A clinical guideline for the use of injection therapy by physiotherapists. Relevant NICE guidance.

Administration

PATIENT GROUP DIRECTION (PGD) FOR

LIDOCAINE (LIGNOCAINE) 0.5%, 1% & 2% INJECTION

Clinical Authorisation	
Lead Doctor	Dr John Devapriam, Medical Director Signature:  Date: 4/4/19
Lead Pharmacist	Dr Alex Johnson, Prescribing Support Pharmacist Signature:  Date: 10.4.19
Snr Podiatrist	Philippa Ball, Orthopaedic Practitioner Podiatrist  Signature: _____ Date: 9.4.19
Snr Physiotherapist	Julie Reynolds, Senior Physiotherapist Signature:  Date: 8.4.19
Organisational Authorisation	
On behalf of the Worcestershire Health & Care NHS Trust	Michelle Clarke, Director of Nursing & Quality Signature:  Date: 4/4/19

